Group 1 - The core stock of the company, 基石药业, has seen a price increase of over 6%, with a cumulative rise of more than 25% in the month [1] - As of the report, the stock is trading at 6.68 HKD with a transaction volume of 1.02 million HKD [1] - On February 23, 基石药业 announced that its PD-L1 antibody,舒格利单抗, has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for a new indication in the treatment of non-small cell lung cancer (NSCLC) [1] - This approval follows the European Commission's (EC) authorization obtained in July 2024, marking a significant breakthrough in the European core market [1] Group 2 - The company's core asset, CS2009, a tri-specific antibody targeting PD-1/VEGF/CTLA-4, has recently received FDA approval for its Phase II clinical trial IND application for advanced solid tumors [1] - This approval signifies an important advancement in the global development of this innovative immunotherapy [1]
基石药业-B再涨超6% 月内涨超25% 舒格利单抗III期NSCLC获英国正式批准